However, glioma and colon cancer patients with a higher YBX3 expression tended to benefit more from chemotherapy than those with a lower YBX3 expression, with P-values of 0.065 and 0.011 for glioma and colon cancer, respectively (Supplementary Figure S1–5A). This evidence concerns the gene YBX3 and malignant colon neoplasm.